Wall Street Zen Downgrades Telix Pharmaceuticals (NASDAQ:TLX) to Sell

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts also recently issued reports about the company. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research report on Tuesday, January 27th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Price Performance

TLX opened at $7.10 on Friday. The business has a fifty day moving average price of $8.07 and a 200 day moving average price of $9.77. Telix Pharmaceuticals has a 12 month low of $6.87 and a 12 month high of $30.36.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Pier Capital LLC purchased a new stake in Telix Pharmaceuticals in the second quarter valued at $3,037,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth about $217,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $297,000. Millennium Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at about $1,883,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at about $1,097,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.